Amarin (NASDAQ:AMRN) Receives “Buy” Rating from Stifel Nicolaus

Amarin (NASDAQ:AMRN)‘s stock had its “buy” rating restated by equities research analysts at Stifel Nicolaus in a report released on Tuesday, AnalystRatings.com reports.

A number of other research analysts have also issued reports on AMRN. Zacks Investment Research upgraded shares of Amarin from a “hold” rating to a “strong-buy” rating and set a $20.00 price objective for the company in a report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating on shares of Amarin in a report on Wednesday, November 6th. Jefferies Financial Group set a $30.00 price objective on shares of Amarin and gave the company a “buy” rating in a report on Thursday, September 12th. Goldman Sachs Group started coverage on shares of Amarin in a report on Tuesday, October 15th. They issued a “neutral” rating and a $17.00 price objective for the company. Finally, Roth Capital set a $31.00 price objective on shares of Amarin and gave the company a “buy” rating in a report on Friday, September 6th. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $27.73.

Shares of AMRN stock traded up $3.69 on Tuesday, reaching $20.60. The company had a trading volume of 1,964,413 shares, compared to its average volume of 5,669,009. The business’s 50-day moving average is $15.92 and its 200 day moving average is $17.34. The stock has a market capitalization of $6.24 billion, a PE ratio of -52.72 and a beta of 1.14. Amarin has a one year low of $11.78 and a one year high of $23.91. The company has a quick ratio of 3.45, a current ratio of 3.69 and a debt-to-equity ratio of 0.02.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $112.40 million during the quarter, compared to analyst estimates of $110.04 million. Amarin had a negative net margin of 17.42% and a negative return on equity of 26.67%. The firm’s quarterly revenue was up 104.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.08) EPS. On average, sell-side analysts forecast that Amarin will post -0.13 earnings per share for the current fiscal year.

In other Amarin news, Director Lars Ekman sold 91,016 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $15.01, for a total transaction of $1,366,150.16. Following the completion of the transaction, the director now owns 13,500 shares in the company, valued at approximately $202,635. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.75% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in AMRN. DAVENPORT & Co LLC acquired a new stake in shares of Amarin during the 2nd quarter valued at about $3,171,000. Xact Kapitalforvaltning AB lifted its holdings in Amarin by 17.4% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 22,900 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 3,400 shares during the last quarter. Fagan Associates Inc. lifted its holdings in Amarin by 8.1% during the 2nd quarter. Fagan Associates Inc. now owns 53,965 shares of the biopharmaceutical company’s stock valued at $1,046,000 after purchasing an additional 4,025 shares during the last quarter. Ogorek Anthony Joseph NY ADV lifted its holdings in Amarin by 45.3% during the 2nd quarter. Ogorek Anthony Joseph NY ADV now owns 17,800 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 5,550 shares during the last quarter. Finally, NEXT Financial Group Inc lifted its holdings in Amarin by 19.1% during the 2nd quarter. NEXT Financial Group Inc now owns 6,550 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 1,050 shares during the last quarter. Hedge funds and other institutional investors own 45.93% of the company’s stock.

About Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Read More: How does new data get added to a blockchain?

Analyst Recommendations for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.